You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 118 No. 6, June 1982 TABLE OF CONTENTS
  Archives
  •  Online Features
  ORIGINAL CONTRIBUTIONS
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citing articles on HighWire
 •Citing articles on Web of Science (4)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Long-term Continuation of Psoralen and Ultraviolet-A Treatment of Psoriasis

Robert S. Stern, MD; John W. Melski, MD

Arch Dermatol. 1982;118(6):400-403.


Abstract

• We studied the continued reliance on psoralen and ultraviolet-A (PUVA) radiation in 1,172 patients. After an average treatment period of 1.8 years, 937 (80%) patients were still receiving PUVA therapy or planned to use PUVA if their psoriasis flared. We defined both groups as patients who continue to rely on PUVA. Patients with the most extensive disease were least likely to continue receiving therapy. Among 1,079 patients with less than 70% involvement, 890 (82%) patients continued to rely on PUVA after 1.8 years. Factors associated with decreased continuation in this group included the following: age older than 60 years, fair or poor general health, multiple previous hospitalizations for treatment of psoriasis, and unusual reactions to sun exposure. Thus, the ability of PUVA to meet long-term treatment needs varies according to demographic and certain disease factors.

(Arch Dermatol 1982;118:400-403)



Author Affiliations

From the Department of Dermatology, Massachusetts General Hospital (Drs Stern and Melski); the Departments of Dermatology (Drs Stern and Melski) and Medicine (Dr Melski), the Laboratory of Computer Medicine (Dr Melski), the Charles A. Dana Research Institute and HarvardThorndike Laboratory (Drs Stern and Melski), Beth Israel Hospital and Harvard Medical School; and the Center for the Analysis of Health Practices, Harvard School of Public Health (Dr Stern), Boston.


Footnotes

Accepted for publication Jan 18, 1982.

Reprint requests to Laboratory of Computer Medicine, Beth Israel Hospital, 330 Brookline Ave, Boston, MA 02115 (Dr Melski).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

The Koebner (Isomorphic) Response in Psoriasis: Associations With Early Age at Onset and Multiple Previous Therapies
Melski et al.
Arch Dermatol 1983;119:655-659.
ABSTRACT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1982 American Medical Association. All Rights Reserved.